# An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment

> **NCT01074333** · — · TERMINATED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 146 (actual)

## Conditions studied

- Colorectal Neoplasm

## Interventions

- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT01074333
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09
- **Primary completion:** 2011-12
- **Final completion:** 2012-01
- **Target enrollment:** 146 (ACTUAL)
- **Why stopped:** This study was terminated due to low recruitment
- **Last updated:** 2014-06-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01074333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01074333, "An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01074333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*